Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 103

1.

Pharmacological characterization of mitragynine, the primary constituent in Kratom, as a potential medication for opioid use disorder.

McMahon LR, Hiranita T, Wilkerson JL, Oyala JFL, McCurdy CR.

J Pharmacol Toxicol Methods. 2019 Sep - Oct;99:106595. doi: 10.1016/j.vascn.2019.05.012. Epub 2019 Oct 17. No abstract available.

PMID:
31963089
2.

Bioanalytical method development and validation of corynantheidine, a kratom alkaloid, using UPLC-MS/MS, and its application to preclinical pharmacokinetic studies.

King TI, Sharma A, Kamble SH, León F, Berthold EC, Popa R, Cerlati O, Prentice BM, McMahon LR, McCurdy CR, Avery BA.

J Pharm Biomed Anal. 2020 Feb 20;180:113019. doi: 10.1016/j.jpba.2019.113019. Epub 2019 Dec 5.

PMID:
31838282
3.

Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.

Obeng S, Kamble SH, Reeves ME, Restrepo LF, Patel A, Behnke M, Chear NJ, Ramanathan S, Sharma A, León F, Hiranita T, Avery BA, McMahon LR, McCurdy CR.

J Med Chem. 2020 Jan 9;63(1):433-439. doi: 10.1021/acs.jmedchem.9b01465. Epub 2019 Dec 27.

PMID:
31834797
4.

Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users.

Singh D, Yeou Chear NJ, Narayanan S, Leon F, Sharma A, McCurdy CR, Avery BA, Balasingam V.

J Ethnopharmacol. 2020 Mar 1;249:112462. doi: 10.1016/j.jep.2019.112462. Epub 2019 Dec 7.

PMID:
31816368
5.

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.

Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, Liu X, Thummuri D, Yuan Y, Wiegand JS, Pei J, Zhang W, Sharma A, McCurdy CR, Kuruvilla VM, Baran N, Ferrando AA, Kim YM, Rogojina A, Houghton PJ, Huang G, Hromas R, Konopleva M, Zheng G, Zhou D.

Nat Med. 2019 Dec;25(12):1938-1947. doi: 10.1038/s41591-019-0668-z. Epub 2019 Dec 2.

PMID:
31792461
6.

Bioanalytical method development and validation of MES207, a neuropeptide FF receptor antagonist, and its application in preclinical pharmacokinetics.

King TI, Roewekamp AC, Sharma A, Harrison S, Mesangeau C, Mottinelli M, Kamble SH, McCurdy CR, Avery BA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Dec 15;1134-1135:121875. doi: 10.1016/j.jchromb.2019.121875. Epub 2019 Nov 12.

PMID:
31790916
7.

Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids.

Kamble SH, Sharma A, King TI, Berthold EC, León F, Meyer PKL, Kanumuri SRR, McMahon LR, McCurdy CR, Avery BA.

Toxicol Lett. 2020 Feb 1;319:148-154. doi: 10.1016/j.toxlet.2019.11.005. Epub 2019 Nov 7.

PMID:
31707106
8.

Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain.

Cirino TJ, Eans SO, Medina JM, Wilson LL, Mottinelli M, Intagliata S, McCurdy CR, McLaughlin JP.

Front Pharmacol. 2019 Jun 14;10:678. doi: 10.3389/fphar.2019.00678. eCollection 2019.

9.

Kratom policy: The challenge of balancing therapeutic potential with public safety.

Prozialeck WC, Avery BA, Boyer EW, Grundmann O, Henningfield JE, Kruegel AC, McMahon LR, McCurdy CR, Swogger MT, Veltri CA, Singh D.

Int J Drug Policy. 2019 Aug;70:70-77. doi: 10.1016/j.drugpo.2019.05.003. Epub 2019 May 16.

10.

The effects of mitragynine and morphine on schedule-controlled responding and antinociception in rats.

Hiranita T, Leon F, Felix JS, Restrepo LF, Reeves ME, Pennington AE, Obeng S, Avery BA, McCurdy CR, McMahon LR, Wilkerson JL.

Psychopharmacology (Berl). 2019 Sep;236(9):2725-2734. doi: 10.1007/s00213-019-05247-7. Epub 2019 May 17.

PMID:
31098655
11.

Simultaneous quantification of ten key Kratom alkaloids in Mitragyna speciosa leaf extracts and commercial products by ultra-performance liquid chromatography-tandem mass spectrometry.

Sharma A, Kamble SH, León F, Chear NJ, King TI, Berthold EC, Ramanathan S, McCurdy CR, Avery BA.

Drug Test Anal. 2019 Aug;11(8):1162-1171. doi: 10.1002/dta.2604. Epub 2019 May 15.

PMID:
30997725
12.

Benzimidazolone-based selective σ2 receptor ligands: Synthesis and pharmacological evaluation.

Intagliata S, Alsharif WF, Mesangeau C, Fazio N, Seminerio M, Xu YT, Matsumoto RR, McCurdy CR.

Eur J Med Chem. 2019 Mar 1;165:250-257. doi: 10.1016/j.ejmech.2019.01.019. Epub 2019 Jan 9.

PMID:
30685525
13.

Motives for using Kratom (Mitragyna speciosa Korth.) among regular users in Malaysia.

Singh D, Narayanan S, Müller CP, Swogger MT, Chear NJY, Dzulkapli EB, Yusoff NSM, Ramachandram DS, León F, McCurdy CR, Vicknasingam B.

J Ethnopharmacol. 2019 Apr 6;233:34-40. doi: 10.1016/j.jep.2018.12.038. Epub 2018 Dec 28.

PMID:
30594604
14.

Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom).

Kamble SH, Sharma A, King TI, León F, McCurdy CR, Avery BA.

Xenobiotica. 2019 Nov;49(11):1279-1288. doi: 10.1080/00498254.2018.1552819. Epub 2019 Jan 7.

PMID:
30547698
15.

Divergent Cytotoxic and Metabolically Stimulative Functions of Sigma-2 Receptors: Structure-Activity Relationships of 6-Acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79) Derivatives.

Nicholson HE, Alsharif WF, Comeau AB, Mesangeau C, Intagliata S, Mottinelli M, McCurdy CR, Bowen WD.

J Pharmacol Exp Ther. 2019 Feb;368(2):272-281. doi: 10.1124/jpet.118.253484. Epub 2018 Dec 7.

16.

Comparative Pharmacokinetics of Mitragynine after Oral Administration of Mitragyna speciosa (Kratom) Leaf Extracts in Rats.

Avery BA, Boddu SP, Sharma A, Furr EB, Leon F, Cutler SJ, McCurdy CR.

Planta Med. 2019 Mar;85(4):340-346. doi: 10.1055/a-0770-3683. Epub 2018 Nov 16.

PMID:
30452072
17.

The Journey to AAPS 2020: a Reflection from Strategic Planning to PharmSci 360.

Polli JW, McCurdy CR, Wurster DE, DeSilva BS, Bak A, Bendayan R, Meibohm B, Templeton AC, Weiser W; AAPS Leadership.

AAPS J. 2018 Nov 3;21(1):2. doi: 10.1208/s12248-018-0273-y. No abstract available.

PMID:
30392015
18.

The Journey to AAPS 2020: a Reflection from Strategic Planning to PharmSci 360.

Polli JW, McCurdy CR, Wurster DE, DeSilva BS, Bak A, Bendayan R, Meibohm B, Templeton AC, Weiser W; AAPS Leadership.

AAPS PharmSciTech. 2018 Nov;19(8):3325-3327. doi: 10.1208/s12249-018-1200-3. Epub 2018 Nov 3. No abstract available.

PMID:
30390237
19.

Successful treatment of chronic knee pain following localization by a sigma-1 receptor radioligand and PET/MRI: a case report.

Cipriano PW, Lee SW, Yoon D, Shen B, Tawfik VL, Curtin CM, Dragoo JL, James ML, McCurdy CR, Chin FT, Biswal S.

J Pain Res. 2018 Oct 12;11:2353-2357. doi: 10.2147/JPR.S167839. eCollection 2018.

20.

Structure-Based Identification of Potent Natural Product Chemotypes as Cannabinoid Receptor 1 Inverse Agonists.

Pandey P, Roy KK, Liu H, Ma G, Pettaway S, Alsharif WF, Gadepalli RS, Rimoldi JM, McCurdy CR, Cutler SJ, Doerksen RJ.

Molecules. 2018 Oct 13;23(10). pii: E2630. doi: 10.3390/molecules23102630.

Supplemental Content

Loading ...
Support Center